Introduction: Fatigue is a widely reported symptom of Multiple Sclerosis and it is the main Wearing-off Symptom (WoS) in Natalizumab (NTZ) treated patients. Whether fatigue presenting as a WoS exclusively depends on NTZ or is influenced by other factors, such as Mood Disturbances, has not been thoroughly investigated. Objectives: The primary aim of the study is to investigate the possible correlation of fatigue with depression and to compare fatigue as a chronic symptom to fatigue as a WoS. Materials and methods: 87 MS-patients treated with NTZ (both on standard and extended-dose intervals) were asked on the day of infusion to specify whether fatigue was present and if so whether it was habitual or occurred only as a WoS. The population was divided into three main categories: Chronic Fatigue, End Dose Fatigue, No Fatigue. All patients underwent a clinical evaluation comprising EDSS, FSMC, BDI-II, MSQoL-29, STAI-Y, and SDMT. Results: 73 (84 %) patients complained of fatigue. Among them, 30 (34.5 %) complained of End Dose Fatigue and 43 (49.4 %) Chronic Fatigue. BDI-II was higher in those complaining of Chronic Fatigue compared to those complaining of End Dose Fatigue only (16.6 vs. 9.3, p < 0.01), while we found no difference in Mood Disturbances frequency and BDI-II between the No Fatigue and End Dose Fatigue group. Conclusions: These results suggest that depression and Mood Disturbances do not play a role in the End Dose Fatigue phenomenon and that fatigue as a WoS is probably different and strictly related to the NTZ mechanism of action.

Fatigue in natalizumab-treated Multiple Sclerosis patients: How much is wearing-off to blame?

Magro, Giuseppe;Barone, Stefania;Pascarella, Angelo;Bruno, Pietro Antonio;Spano, Giorgio;Buonocore, Jolanda;Mummolo, Cataldo;Iorio, Roberto Di;Saraceno, Adriana;Gambardella, Antonio;Valentino, Paola
2025-01-01

Abstract

Introduction: Fatigue is a widely reported symptom of Multiple Sclerosis and it is the main Wearing-off Symptom (WoS) in Natalizumab (NTZ) treated patients. Whether fatigue presenting as a WoS exclusively depends on NTZ or is influenced by other factors, such as Mood Disturbances, has not been thoroughly investigated. Objectives: The primary aim of the study is to investigate the possible correlation of fatigue with depression and to compare fatigue as a chronic symptom to fatigue as a WoS. Materials and methods: 87 MS-patients treated with NTZ (both on standard and extended-dose intervals) were asked on the day of infusion to specify whether fatigue was present and if so whether it was habitual or occurred only as a WoS. The population was divided into three main categories: Chronic Fatigue, End Dose Fatigue, No Fatigue. All patients underwent a clinical evaluation comprising EDSS, FSMC, BDI-II, MSQoL-29, STAI-Y, and SDMT. Results: 73 (84 %) patients complained of fatigue. Among them, 30 (34.5 %) complained of End Dose Fatigue and 43 (49.4 %) Chronic Fatigue. BDI-II was higher in those complaining of Chronic Fatigue compared to those complaining of End Dose Fatigue only (16.6 vs. 9.3, p < 0.01), while we found no difference in Mood Disturbances frequency and BDI-II between the No Fatigue and End Dose Fatigue group. Conclusions: These results suggest that depression and Mood Disturbances do not play a role in the End Dose Fatigue phenomenon and that fatigue as a WoS is probably different and strictly related to the NTZ mechanism of action.
2025
Anxiety
Chronic fatigue
Depression
End of dose fatigue
Extended dose interval
Fatigue
Wearing off symptoms
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.12317/108062
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact